NEW YORK (
CHANGE IN RATINGS
downgraded at UBS to Neutral from Buy, UBS said. $37 price target. Valuation call.
downgraded at JP Morgan from Overweight to Neutral, JP Morgan said. Valuation call, as the company lags near-term catalysts.
(AMGN - Get Report)
upgraded at Deutsche from Hold to Buy, Deutsche Bank said. $108 price target. Market is not yet pricing in the company's above-average growth.
downgraded at Oppenheimer to Perform from Outperform, Oppenheimer said. Too early to call AP26113 winner.
(BTU - Get Report)
downgraded at Goldman from Buy to Neutral, Goldman Sachs said. Valuation call, based on a $28 price target.
Check Point Software
upgraded at JP Morgan from Neutral to Overweight, JP Morgan said. $50 price target. Investor expectations are low, but the company generates consistent cash flow.
upgraded at Goldman to Buy, Goldman Sachs said. Company delivers above-average growth and should soon see a double-digit price hike.
(DNKN - Get Report)
rated new Hold at Miller Tabak. Valuation call, based on a $34 price target.
upgraded at JP Morgan from Underweight to Overweight, JP Morgan said. New analyst has a $71 price target. Company is facing favorable regulations and pays an above-average dividend.
downgraded at Goldman from Buy to Neutral, Goldman Sachs said. Valuation call, as the stock has outperformed its peers by 11% year-to-date.
downgraded at BMO from Outperform to Market Perform, BMO Capital said. $130 price target. Company is seeing slower core business growth and recently announced some management changes.
downgraded at Baird from Outperform to Neutral, Robert Baird said. $30 price target. Company is facing increased competition from EMC and others.
downgraded at Sterne to Neutral, Sterne Agee said. Valuation call, as the stock has outperformed its peers in recent years.
Omega Healthcare Investors
downgraded at Jefferies to Hold from Buy, Jefferies said. Fiscal cliff looms.
downgraded at Argus from Buy to Hold, Argus said. Company faces growth headwinds in the near term.